At the AACR-NCI-EORTC conference for molecular targets (#Targets19) at Boston, we presented our latest preclinical research on treating colon cancer and boosting anti-PD-1 immunotherapy with our “targeted nutrient deprivation” technology.
Filtricine research on scientific conference for cancer treatment
Comments